Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Effects of AMN107, a Novel Aminopyrimidine Tyrosine Kinase Inhibitor, on Human Mast Cells Bearing Wild-Type or Mutated Codon 816 c-kit.

Srdan Verstovsek, MD, PhD, Cem Akin, MD, Giles J. Francis, MD, Manshouri Taghi, MS, BA, Ly Huynh, BS, Paul W. Manley, MD, Leila Alland, MD, Margaret Dugan, PhD, Jorge E. Cortes, MD, Kantarjian M. Hagop, MD

Blood (2005) 106 (11): 3528.

https://doi.org/10.1182/blood.V106.11.3528.3528

Published: 2005

Journal Articles

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

Bronno van der Holt, Bob Löwenberg, Alan K. Burnett, Wolfgang U. Knauf, John Shepherd, Pier Paolo Piccaluga, Gert J. Ossenkoppele, Gregor E. G. Verhoef, Augustin Ferrant, Michael Crump, Dominik Selleslag, Matthias Theobald, Martin F. Fey, Edo Vellenga, Margaret Dugan, Pieter Sonneveld, on behalf of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the United Kingdom Medical Research Council (MRC)

Blood (2005) 106 (8): 2646–2654.

https://doi.org/10.1182/blood-2005-04-1395

Published: 2005

Journal Articles

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Mirna Golemovic, M.S., Miloslav Beran, M.D., Ph.D., Francis Giles, M.D., Taghi Manshouri, M.S.C., Deborah Thomas, M.D., Jorge Cortes, M.D., Paul Manley, M.D., Leila Alland, M.D., Patricia Rae, B.S.C., Margaret Dugan, M.D., Zeev Estrov, M.D., Ralph B. Arlinghaus, Ph.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2004) 104 (11): 2737.

https://doi.org/10.1182/blood.V104.11.2737.2737

Published: 2004

Journal Articles

Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia.

Bronno van der Holt, Pieter Sonneveld, Alan K. Burnett, Paula J.M. Vossebeld, Berna Beverloo, Gerd Rosenkranz, Margaret Dugan, Wim L.J. van Putten, Keith Wheatley, Bob Lowenberg

Blood (2004) 104 (11): 863.

https://doi.org/10.1182/blood.V104.11.863.863

Published: 2004

Journal Articles

A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.

Francis J. Giles, MD, Thomas Fischer, MD, Jorge Cortes, MD, James Beck, MD, Farhad Ravandi-Kashani, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Bin Peng, PhD, Patricia E. Rae, BSc, Glen Laird, Samil Sharma, MD, Margaret Dugan, MD, Maher Albitar, MD, Kapil M. Bhalla, MD

Blood (2004) 104 (11): 1802.

https://doi.org/10.1182/blood.V104.11.1802.1802

Published: 2004

NARROW

Effects of AMN107, a Novel Aminopyrimidine Tyrosine Kinase Inhibitor, on Human Mast Cells Bearing Wild-Type or Mutated Codon 816 c-kit.

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia.

A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Effects of AMN107, a Novel Aminopyrimidine Tyrosine Kinase Inhibitor, on Human Mast Cells Bearing Wild-Type or Mutated Codon 816 c-kit.

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia.

A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only